Economic Outcomes

Restrictive blood transfusion practices are associated with improved patient outcomes. (opens new window)

Goodnough LT, Maggio P, Hadhazy E, Shieh L, Hernandez-Boussard T, Khari P, Shah N.

Source‎: Transfusion 2014;54(10 Pt 2):2753-9.

Indexed‎: PubMed 24995770

DOI‎: 10.1111/trf.12723

https://www.ncbi.nlm.nih.gov/pubmed/24995770 (opens new window)

Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. (opens new window)

Leahy MF, Hofmann A, Towler S, Trentino KM, Burrows SA, Swain SG, Hamdorf J, Gallagher T, Koay A, Geelhoed GC, Farmer SL.

Source‎: Transfusion 2017;57(6):1347-58.

Indexed‎: PubMed 28150313

DOI‎: 10.1111/trf.14006

https://www.ncbi.nlm.nih.gov/pubmed/28150313 (opens new window)

Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. (opens new window)

MacLaren R, Sullivan PW.

Source‎: Value Health 2005;8(2):105-16.

Indexed‎: PubMed 15804319

DOI‎: 10.1111/j.1524-4733.2005.04006.x

https://www.ncbi.nlm.nih.gov/pubmed/15804319 (opens new window)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (opens new window)

Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T, Moos RM, Volbracht J, Manz MG, Spahn DR

Source‎: Transfusion 2015;55(12):2807-15.

Indexed‎: PubMed 26264557

DOI‎: 10.1111/trf.13260

https://www.ncbi.nlm.nih.gov/pubmed/26264557 (opens new window)

Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. (opens new window)

Nardi G, Agostini V, Rondinelli B, Russo E, Bastianini B, Bini G, Bulgarelli S, Cingolani E, Donato A, Gambale G, Ranaldi G

Source‎: Crit Care 2015;19:83.

Indexed‎: PubMed 25880548

DOI‎: 10.1186/s13054-015-0817-9

https://www.ncbi.nlm.nih.gov/pubmed/25880548 (opens new window)

The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. (opens new window)

Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, Cook L, Kawahara T, Perel P, Prieto-Merino D, Ramos M, Cairns J, Guerriero C.

Source‎: Health Technol Assess 2013;17(10):1-79.

Indexed‎: PubMed 23477634

DOI‎: 10.3310/hta17100

https://www.ncbi.nlm.nih.gov/pubmed/23477634 (opens new window)

Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. (opens new window)

Stein DM, Dutton RP, Kramer ME, Scalea TM.

Source‎: J Trauma 2009;66(1):63-72.

Indexed‎: PubMed 19131807

DOI‎: 10.1097/TA.0b013e318191bc8a

https://www.ncbi.nlm.nih.gov/pubmed/19131807 (opens new window)

Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation. (opens new window)

Zilberberg MD, Shorr AF.

Source‎: BMC Health Serv Res 2007;7:138.

Indexed‎: PubMed 17764560

DOI‎: 10.1186/1472-6963-7-138

https://www.ncbi.nlm.nih.gov/pubmed/17764560 (opens new window)

INTENSIVE AND CRITICAL CARE

Economic Outcomes

English

Economic Outcomes

https://assetsnffrgf-a.akamaihd.net/assets/ct/1add6d1d93/images/syn_placeholder_sqr.png

Restrictive blood transfusion practices are associated with improved patient outcomes. (opens new window)

Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. (opens new window)

Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. (opens new window)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (opens new window)

Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. (opens new window)

The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. (opens new window)

Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. (opens new window)

Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation. (opens new window)

Hospital Liaison Committee (HLC)

Medical Information Packets

Videos

Economic Outcomes

Select Your Language

Share